Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Scholar Rock Holding (SRRK) is now available.
Scholar Rock Holding Corporation revealed promising results from a preclinical study at the American Diabetes Association’s 84th Scientific Sessions, which demonstrated potential benefits of their drug SRK-439 in combination with GLP-1 receptor agonists for weight management. In a mouse model, SRK-439 not only mitigated lean mass loss during treatment but also reduced fat mass rebound after the cessation of the drug. These findings suggest SRK-439 could offer a healthier body composition for those struggling with obesity. Additionally, the company has started a Phase 2 trial to evaluate the effectiveness of another drug, apitegromab, in preserving lean muscle mass in obese individuals.
For a thorough assessment of SRRK stock, go to TipRanks’ Stock Analysis page.
